

ADAPTABLE


#ACC21



AMERICAN
COLLEGE of
CARDIOLOGY

Trial Description: Patients with ASCVD were randomized to aspirin 81 mg vs. aspirin 325 mg.

$p = 0.75$



Aspirin 81 mg
(n = 7,540)



Aspirin 325 mg
(n = 7,536)

RESULTS

- Primary effectiveness outcome of all-cause death, MI, or stroke at 12 months: 7.3% of the aspirin 81 mg group vs. 7.5% of the aspirin 325 mg group ($p = 0.75$)
- Primary safety outcome of major bleeding requiring blood transfusion at 12 months: 0.6% of the aspirin 81 mg group vs. 0.6% of the aspirin 325 mg group ($p = 0.41$)

CONCLUSIONS

- Among patients with ASCVD, aspirin 325 mg was not superior compared with 81 mg
- Aspirin 325 mg was not associated with a reduction in all-cause death, MI, or stroke compared with 81 mg daily
- Major bleeding was similar between the treatment groups

Jones WS, et al. *N Engl J Med* 2021;384(21):1981-1990